CASI Pharmaceuticals Inc./$CASI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Ticker
$CASI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
233
ISIN
KYG1933S1012
Website
CASI Metrics
BasicAdvanced
$19M
-
-$2.55
0.63
-
Price and volume
Market cap
$19M
Beta
0.63
52-week high
$2.92
52-week low
$1.10
Average daily volume
201K
Financial strength
Current ratio
0.806
Quick ratio
0.602
Total debt to equity
-229.145
Interest coverage (TTM)
-45.92%
Profitability
EBITDA (TTM)
-38.248
Gross margin (TTM)
41.31%
Net profit margin (TTM)
-129.05%
Operating margin (TTM)
-128.24%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-50.88%
Return on equity (TTM)
-1,094.50%
Valuation
Price to revenue (TTM)
0.607
Price to book
-2.3
Price to tangible book (TTM)
-2.24
Growth
Revenue change (TTM)
8.39%
Earnings per share change (TTM)
11.85%
3-year revenue growth (CAGR)
-2.16%
10-year revenue growth (CAGR)
91.44%
3-year earnings per share growth (CAGR)
4.18%
10-year earnings per share growth (CAGR)
-11.71%
CASI News
AllArticlesVideos
CASI Pharmaceuticals Provides Business and Clinical Update
Accesswire·1 month ago
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
Accesswire·1 month ago
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CASI Pharmaceuticals Inc. stock?
CASI Pharmaceuticals Inc. (CASI) has a market cap of $19M as of June 30, 2025.
What is the P/E ratio for CASI Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for CASI Pharmaceuticals Inc. (CASI) stock is 0 as of June 30, 2025.
Does CASI Pharmaceuticals Inc. stock pay dividends?
No, CASI Pharmaceuticals Inc. (CASI) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next CASI Pharmaceuticals Inc. dividend payment date?
CASI Pharmaceuticals Inc. (CASI) stock does not pay dividends to its shareholders.
What is the beta indicator for CASI Pharmaceuticals Inc.?
CASI Pharmaceuticals Inc. (CASI) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.